Acorda Therapeutics, Inc. (ACOR) News

Acorda Therapeutics, Inc. (ACOR): $0.48

0.01 (+3.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

Filter ACOR News Items

ACOR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ACOR News From Around the Web

Below are the latest news stories about Acorda Therapeutics Inc that investors may wish to consider to help them evaluate ACOR as an investment opportunity.

Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y., January 04, 2022--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Yahoo | January 4, 2022

John Varian Joins Acorda Therapeutics Board of Directors

ARDSLEY, N.Y., January 03, 2022--John Varian joins Acorda Therapeutics Board of Directors

Yahoo | January 3, 2022

Multiple Sclerosis Market to Witness Notable Growth by 2027 Covid-19 Analysis | Abbvie, Acorda Therapeutics

This Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves

OpenPR | December 15, 2021

Ataxia Market Expected to Expand at a Steady 2021-2028 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc.

"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are

OpenPR | December 13, 2021

Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B

Business Wire | December 13, 2021

Worldwide Multiple Sclerosis Drugs Industry to 2027 - Featuring Abbvie, Acorda Therapeutics and Biogen Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. The report is based on a comprehensive research of the entire global multiple sclero

Business Wire | December 10, 2021

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update

Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 587,000 shares, an increase of 34.9% from the October 31st total of 435,000 shares. Based on an average daily trading volume, of 142,400 shares, the days-to-cover ratio is presently 4.1 [] The post Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update appeared first on ETF Daily News .

ETF Daily News | December 4, 2021

Geode Capital Management LLC Has $350,000 Stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Geode Capital Management LLC raised its stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 13.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,562 shares of the biopharmaceutical companys stock after buying an additional 8,706 shares during the quarter. Geode Capital Management LLC []

Dakota Financial News | November 28, 2021

Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

ARDSLEY, N.Y., November 09, 2021--Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

Yahoo | November 9, 2021

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

ARDSLEY, N.Y., November 09, 2021--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

Yahoo | November 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4528 seconds.